Literature DB >> 19115971

Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005.

Sandra S Richter1, Kristopher P Heilmann, Cassie L Dohrn, Fathollah Riahi, Susan E Beekmann, Gary V Doern.   

Abstract

BACKGROUND: The impact of pediatric 7-valent pneumococcal conjugate vaccination (PCV-7) on the population of Streptococcus pneumoniae in the United States was examined by determining the serotypes, antimicrobial resistance profiles, and genetic relatedness of isolates from patients with invasive and noninvasive infections during the 2004-2005 respiratory illness season.
METHODS: Susceptibility testing, serotyping, and pulsed-field gel electrophoresis analysis were performed on 1647 S. pneumoniae isolates obtained from 41 US medical centers in 2004-2005 as part of a longitudinal antimicrobial resistance surveillance program. The results were compared with surveillance data from earlier periods.
RESULTS: From the 1999-2000 to the 2004-2005 respiratory illness season, the prevalence of isolates with intermediate penicillin resistance (minimum inhibitory concentration, 0.1-1 microg/mL) increased from 12.7% to 17.9%, prevalence of penicillin-resistant isolates (minimum inhibitory concentration, >or=2 microg/mL) decreased from 21.5% to 14.6%, and prevalence of isolates resistant to erythromycin increased from 25.7% to 29.1% among S. pneumoniae isolates. The prevalence of multidrug resistance among isolates did not change (22.4% in 1999-2000 and 20.0% in 2004-2005). Sixty different serotypes were recognized among the isolates from 2004-2005; predominant serotypes were 19A (14.5%), 3 (11.2%), 6A (7.1%), 19F (7%), and 11A (6%). Serotypes that were included in PCV-7 accounted for 16.3% of isolates; 28.4% of strains isolated had PCV-7-related serotypes, and the remaining 55.3% of isolates had serotypes that were unrelated to PCV-7. The serotype distribution of the penicillin-resistant S. pneumoniae population changed from 1999-2000 to 2004-2005, with an increase in the prevalence of serotype 19A (1.5% to 35.4%) and serotype 35B (1.2% to 12.5%) and a decrease in the prevalence of most PCV-7 serotypes, including 23F (16.1% to 5%), 9V (16.1% to 4.2%), 6B (13.7% to 3.8%), and 14 (18.5% to 2.9%).
CONCLUSIONS: The penicillin-resistant S. pneumoniae population has changed; most isolates are now closely related to 2 Pneumococcal Molecular Epidemiology Network clones that increased in prevalence from 1999-2000 to 2004-2005 (Taiwan(19F)-14 [14.6% to 36.7%; 60% were serotype 19A] and Utah(35B)-24 [0.9% to 16.3%]).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19115971     DOI: 10.1086/595857

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  44 in total

1.  Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.

Authors:  Seong-Ho Choi; Jin-Won Chung; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

2.  A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene.

Authors:  Juan J Calix; Moon H Nahm
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

Review 3.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

4.  Evaluation of pneumococcal serotyping by multiplex PCR and quellung reactions.

Authors:  Sandra S Richter; Kristopher P Heilmann; Cassie L Dohrn; Fathollah Riahi; Daniel J Diekema; Gary V Doern
Journal:  J Clin Microbiol       Date:  2013-09-11       Impact factor: 5.948

5.  Clonal evolution leading to maintenance of antibiotic resistance rates among colonizing Pneumococci in the PCV7 era in Portugal.

Authors:  Alexandra S Simões; Liliana Pereira; Sónia Nunes; António Brito-Avô; Hermínia de Lencastre; Raquel Sá-Leão
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

6.  Streptococcus pneumoniae serotype 9A isolates contain diverse mutations to wcjE that result in variable expression of serotype 9V-specific epitope.

Authors:  Juan J Calix; Melissa B Oliver; Logan K Sherwood; Bernard W Beall; Susan K Hollingshead; Moon H Nahm
Journal:  J Infect Dis       Date:  2011-09-09       Impact factor: 5.226

7.  Noninvasive pneumococcal clones associated with antimicrobial nonsusceptibility isolated from children in the era of conjugate vaccines.

Authors:  Martha McElligott; Imelda Vickers; Mary Meehan; Mary Cafferkey; Robert Cunney; Hilary Humphreys
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

Review 8.  Intratympanic Gene Delivery of Antimicrobial Molecules in Otitis Media.

Authors:  Sung K Moon; David J Lim
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

9.  New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine.

Authors:  Janet R Casey; Diana G Adlowitz; Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

10.  Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae.

Authors:  Dylan R Pillai; Dea Shahinas; Alla Buzina; Remy A Pollock; Rachel Lau; Krishna Khairnar; Andrew Wong; David J Farrell; Karen Green; Allison McGeer; Donald E Low
Journal:  BMC Genomics       Date:  2009-12-30       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.